Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Confident in the Future of Bria-IMT Following its Demonstrated Success in Clinical Trials

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 01:46pm EDT

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, sees a promising future for its lead product candidate, Bria-IMT. An article discussing the company reads, “The company recently presented promising results for two of its clinical studies (monotherapy and combination study of Bria-IMT with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]) for patients with advanced breast cancer during the 2018 San Antonio Breast Cancer Symposium in Texas (http://nnw.fm/5YriX).  … ‘I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,’ Dr. Bill Williams, BriaCell’s president & CEO, said of the company’s presentation at the international symposium that attracted over 7,000 academic and private physicians and researchers (http://nnw.fm/Po3A0).  ‘These findings also reinforce our product development strategy for Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.’”

To view the full article, visit http://nnw.fm/Tm2FS

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Copyright © 2015 - 2019 NetworkNewsWire, source NetworkNewsWire

Stocks mentioned in the article
ChangeLast1st jan.
BRIACELL THERAPEUTICS CORP 4.76% 0.11 Delayed Quote.37.50%
MERCK AND COMPANY 0.07% 82.35 Delayed Quote.7.77%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
03/25MERCK AND : NGM Biopharma Sets IPO at 6.67 Million Shares Priced at $14-$16 Each
DJ
03/22UPS to Test In-Home Vaccine Service in U.S. -Reuters
DJ
03/22UPS eyes in-home health services with U.S. vaccine project
RE
03/20MERCK AND : NGM Bio Extend Therapeutics Collaboration to 2022
DJ
03/20MERCK : and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaborat..
BU
03/20BRISTOL MYERS SQUIBB : Overheard
DJ
03/19BRISTOL MYERS SQUIBB : Correction to Bristol-Myers Squibb Overheard Article
DJ
03/19If This Is Failure, Show Me Success -- Overheard
DJ
03/18MERCK AND : New Treatment Option Now Available in Canada for Newly Diagnosed Pat..
AQ
03/16ROCHE : Key drugs from Merck, Roche win wider EU approvals
AQ
More news
Financials ($)
Sales 2019 44 448 M
EBIT 2019 14 986 M
Net income 2019 9 947 M
Debt 2019 16 436 M
Yield 2019 2,67%
P/E ratio 2019 20,88
P/E ratio 2020 17,70
EV / Sales 2019 5,15x
EV / Sales 2020 4,82x
Capitalization 213 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 86,6 $
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.77%212 563
JOHNSON & JOHNSON5.86%363 761
NOVARTIS10.09%237 528
ROCHE HOLDING LTD.10.42%232 888
PFIZER-4.03%232 565
ELI LILLY AND COMPANY12.23%134 522